Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus SETHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus SETHOTOPE.
DRAXIMAGE MDP-25 vs SETHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
SETHOTOPE is a radiolabeled monoclonal antibody that binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells, delivering beta radiation (177Lu) to cause DNA damage and cell death.
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
1.0 mg IV every 12 hours for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives
Terminal elimination half-life: 12 hours (range 10-14 h); clinically, dosing interval is 12-24 h to maintain therapeutic levels
Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion)
Renal: 70% as unchanged drug; fecal: 25% as metabolites; biliary: 5%
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical